Faivre J, Forman D, Estève J, Gatta G
Côte d'Or Cancer Registry, University of Dijon, Faculté de Médecine, France.
Eur J Cancer. 1998 Dec;34(14 Spec No):2167-75. doi: 10.1016/s0959-8049(98)00329-3.
The EUROCARE study is a European Union project to collect survival data from population-based cancer registries and analyse them according to standardised procedures. We investigated and compared oesophageal and gastric cancer survival in 17 countries between 1985 and 1989. Time trends in survival over the 1978-1989 period were also investigated in 13 countries. The overall European 1-year relative survival rates were 33% for oesophageal cancer and 40% for gastric cancer. The corresponding 5-year relative survival rates were 10 and 21%, respectively. Important intercountry survival differences exist within Europe for oesophageal and gastric cancer. Taking the European average as the reference, the relative risk (RR) of death at 5 years was at least 30% higher in Denmark, Poland, Estonia and Slovenia for oesophageal cancer and in Denmark, England, Scotland and Poland for gastric cancer. In the other countries survival figures were close to the European average. Gender had little influence on survival, whilst age at diagnosis was inversely related to prognosis. There was a slight improvement between 1978 and 1989 in 5-year overall relative survival rates for both oesophageal cancer (RR = 0.80, 95% confidence interval (CI) 0.72-0.90) and gastric cancer (RR = 0.88, 95% CI 0.82-0.94). Differences in quality of care and stage at diagnosis can explain in part the differences in survival found in the EUROCARE countries. Significant improvement in prognosis has still to be achieved.
欧洲癌症和治愈评估研究(EUROCARE)是一个欧盟项目,旨在从基于人群的癌症登记处收集生存数据,并按照标准化程序进行分析。我们调查并比较了1985年至1989年间17个国家的食管癌和胃癌生存率。还对13个国家1978 - 1989年期间的生存时间趋势进行了调查。欧洲食管癌的总体1年相对生存率为33%,胃癌为40%。相应的5年相对生存率分别为10%和21%。在欧洲,食管癌和胃癌在不同国家间存在显著的生存差异。以欧洲平均水平为参照,丹麦、波兰、爱沙尼亚和斯洛文尼亚的食管癌患者5年死亡相对风险(RR)至少高出30%,丹麦、英格兰、苏格兰和波兰的胃癌患者5年死亡相对风险至少高出30%。在其他国家,生存数据接近欧洲平均水平。性别对生存率影响不大,而确诊时的年龄与预后呈负相关。1978年至1989年间,食管癌(RR = 0.80,95%置信区间(CI)0.72 - 0.90)和胃癌(RR = 0.88,95%CI 0.82 - 0.94)的5年总体相对生存率略有提高。医疗质量和确诊时的分期差异可以部分解释EUROCARE研究涉及国家间生存率的差异。预后仍有待显著改善。